Worth reading
23Immaterial
Scored from 3 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&AFiscal year ending March 20262 items taken from the company’s own explanation
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- Questions How long will out-licensing activities for PPMX-T003 and PPMX-T002 continue, and what are the prospects going forward? / Answer For PPMX-T003, the company is selecting potential partners and providing information to multiple companies, while continuing out-licensing activities with a view to expanding indications beyond polycythemia vera. For PPMX-T002, activities will focus on potential partners seeking to strengthen the development of radiopharmaceuticals.
- Questions When will Phase 1 trials for PPMX-T004 begin, and when will out-licensing activities begin? / Answer The antibody MCB and engineering batches are scheduled to be manufactured between January 2027 and March 2028, after which preparations for GLP toxicity studies will begin. Phase 1 is scheduled to start after the GLP toxicity studies are completed.
- Questions Will the business model be reviewed in response to the review of the Growth Market listing maintenance criteria? / Answer There are no decisions that can be announced at this time, but the company is considering the matter from various perspectives with a view to meeting the revised criteria.
- Questions Why are negotiations for out-licensing PPMX-T003 and PPMX-T002 taking so long, and what are the bottlenecks? / Answer One reason for PPMX-T003 is that the Phase 1 trial took time and the available clinical data only extend through Phase 1. For PPMX-T002, an unstable supply of actinium-225 had been a bottleneck, but supply conditions are improving globally.
New initiatives
- Out-licensing activities for PPMX-T003 with a view to expanding indications beyond polycythemia vera
- Out-licensing activities for PPMX-T002 focused on potential partners seeking to strengthen the development of radiopharmaceuticals
- Manufacture of the PPMX-T004 antibody MCB and engineering batches, and preparations for GLP toxicity studies
- Review of the business model aimed at meeting the revised Growth Market listing maintenance criteria
| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Key points of the Q&A | Questions How long will out-licensing activities for PPMX-T003 and PPMX-T002 continue, and what are the prospects going forward? / Answer For PPMX-T003, the company is selecting potential partners and providing information to multiple companies, while continuing out-licensing activities with a view to expanding indications beyond polycythemia vera. For PPMX-T002, activities will focus on potential partners seeking to strengthen the development of radiopharmaceuticals., Questions When will Phase 1 trials for PPMX-T004 begin, and when will out-licensing activities begin? / Answer The antibody MCB and engineering batches are scheduled to be manufactured between January 2027 and March 2028, after which preparations for GLP toxicity studies will begin. Phase 1 is scheduled to start after the GLP toxicity studies are completed., Questions Will the business model be reviewed in response to the review of the Growth Market listing maintenance criteria? / Answer There are no decisions that can be announced at this time, but the company is considering the matter from various perspectives with a view to meeting the revised criteria., Questions Why are negotiations for out-licensing PPMX-T003 and PPMX-T002 taking so long, and what are the bottlenecks? / Answer One reason for PPMX-T003 is that the Phase 1 trial took time and the available clinical data only extend through Phase 1. For PPMX-T002, an unstable supply of actinium-225 had been a bottleneck, but supply conditions are improving globally. |
| New initiatives | Out-licensing activities for PPMX-T003 with a view to expanding indications beyond polycythemia vera, Out-licensing activities for PPMX-T002 focused on potential partners seeking to strengthen the development of radiopharmaceuticals, Manufacture of the PPMX-T004 antibody MCB and engineering batches, and preparations for GLP toxicity studies, Review of the business model aimed at meeting the revised Growth Market listing maintenance criteria |
Items this document does not state (27)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company held a briefing on financial results for analysts and institutional investors on 18 May 2026 and disclosed a summary of the Q&A.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.